Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Pharma Industry News Is this the biomarker breakthrough Longeveron Inc. needs to reach Phase 3? Can biomarker-linked response boost laromestrocel’s Phase 3 prospects? Explore regulatory, financial, and industry implications. bySoujanya RaviFebruary 28, 2026